Targeting AMPK Networks for Male Reproductive Health: Mechanisms and Emerging Therapies

Review argues AMPK—an energy-sensing enzyme disrupted by obesity and diabetes—could be a druggable target for male infertility

Journal: Cells | Published: 2026-04-29 | Type: Narrative Review | PMID: 42121908 Authors: Rahman et al.; Wayne State University (Karmanos Cancer Institute), King Saud University, Imam Mohammad Ibn Saud Islamic University, Kyung Hee University (10 authors total) Funding/COI: National Research Foundation of Korea; no COI declared

Summary

AMP-activated protein kinase (AMPK) is a cellular energy sensor that, when disrupted by obesity, diabetes, or aging, impairs spermatogenesis, sperm motility, and testosterone synthesis. This narrative review maps AMPK's role across the male reproductive system—Sertoli cells, Leydig cells, and sperm themselves—and argues that pharmacological AMPK activators like metformin and AICAR, plus lifestyle interventions, could restore reproductive function in metabolically compromised men. The authors are candid that tissue selectivity, optimal dosing, and clinical translation remain unsolved problems.

Claims

• AMPK regulates spermatogenesis by coordinating the mTOR, SIRT1, PGC-1α, and FOXO signaling networks
• AMPK activation in Sertoli cells supports metabolic provisioning of developing sperm; Leydig cell AMPK governs testosterone synthesis
• Metabolic stressors (obesity, diabetes, environmental toxins) suppress AMPK activity, leading to mitochondrial dysfunction, elevated oxidative stress, and impaired sperm capacitation and acrosome reaction
• Metformin and AICAR (both AMPK activators) "have shown promise" in restoring metabolic balance and improving reproductive outcomes—no specific effect sizes cited in the abstract
• Combinatorial strategies pairing AMPK activators with antioxidants and autophagy modulators are proposed to have synergistic potential
• Most supporting evidence appears to derive from animal models; the MeSH terms index both "Humans" and "Animals"

Study Quality

This is a narrative review, the weakest study design for establishing causal claims. There is no systematic search protocol, no PRISMA flow, no risk-of-bias assessment of included studies, and no quantitative synthesis. The abstract makes no reference to how papers were selected or excluded, which means cherry-picking cannot be ruled out. The review synthesizes basic science (mostly rodent and cell-line data) with sparse human clinical data, and the leap from molecular mechanism to therapeutic recommendation is not bridged by clinical trial evidence.

Ten authors from four institutions on three continents is an unusually large author list for a mechanistic review; the Kyung Hee University contingent (eight of ten authors) leans on traditional Korean medicine framing ("College of Korean Medicine") which may reflect institutional bias toward natural bioactive compounds as AMPK modulators.

Red Flags

• Narrative review with no disclosed search methodology — selection bias is unquantifiable
• No original data; the review summarizes others' findings without meta-analytic rigor
• Metformin's reproductive effects in men are specifically under-studied in RCTs; the "promise" claim is mostly preclinical
• "Natural bioactive substances" are listed alongside metformin without distinguishing their evidence quality
• No COI disclosed despite multi-institutional, multi-country authorship — omissions here are notable, not reassuring
• Abstract-level language ("possible therapeutic approach," "shown promise," "may yield synergistic advantages") signals low confidence in the underlying evidence, acknowledged by the authors themselves
• Korean government funding with a heavy Kyung Hee "College of Korean Medicine" author list raises concern that the natural compound sections may be boosted beyond what the evidence warrants

Strengths

• Government-funded (National Research Foundation of Korea), not industry-funded — lower risk of commercial bias on the pharmacological sections
• AMPK is a well-characterized pathway with decades of mechanistic literature; the molecular framework described is not speculative
• Authors explicitly acknowledge the clinical translation gap rather than overstating readiness
• Connecting metabolic syndrome to male infertility via a specific molecular mechanism is a genuinely useful framing for researchers

Verdict

This review is useful as a molecular map—if you want to understand how AMPK connects metabolic disease to sperm dysfunction mechanistically, it covers the territory. It is not useful as evidence that any AMPK-targeted therapy actually improves human fertility outcomes. The therapeutic sections are extrapolations from rodent and cell-line work dressed in clinical language. Read it as a hypothesis generator, not a treatment guide. The lack of a systematic methodology and the undisclosed COI make it unsuitable to cite in support of clinical claims.